Q3 FY23 Earnings Presentation

Environmental, social & governance Long-range objectives & targets Table of Executive Portfolio Financial Guidance & Contents Summary Highlights Highlights Assumptions ESG Appendix For more information, visit Medtronic.com 2021 ESG Investor Briefing 2022 Integrated Performance Report 2022 Global Inclusion, Diversity & Equity Report Patient Safety & Product Quality 10% Reduction in aggregate product complaint rate for identified product families by FY25 vs. FY20 Access & Innovation 20% MDT revenue from products and therapies released in the prior 36 months by FY25 85M Patients served annually by FY25 Inclusion, Diversity & Equity 45% Global management positions held by women by FY26 30% U.S. management positions held by ethnically diverse talent by FY26 Climate Stewardship 50% Reduction in greenhouse gas omission intensity by FY25 50% Sourced energy from renewable and alternative sources by FY25 Carbon Neutral In our operations by FY30 Net Zero Emissions By 2045 Product Stewardship 25% Reduction in packaging waste for targeted high- volume products by FY25 vs. FY21 35% Reduction in paper associated with Instructions for Use (IFUS) by FY27 vs. FY21 23 Q3 FY23 Earnings Presentation | February 21, 2023 Medtronic

View entire presentation